Padula, Anthony S.
Pappas, Dimitrios A. http://orcid.org/0000-0001-8338-027X
Fiore, Stefano
Blachley, Taylor S.
Ford, Kerri
Emeanuru, Kelechi
Kremer, Joel M.
Funding for this research was provided by:
The RA Registry was sponsored by CorEvitas, LLC and this analysis was funded by Sanofi.
Article History
Received: 22 April 2022
Accepted: 13 November 2022
First Online: 21 December 2022
Declarations
:
: All participating investigators were required to obtain full board approval for conducting research involving human subjects. Sponsor approval and continuing review were obtained through a central IRB (New England Independent Review Board, NEIRB No. 120160610). For academic investigative sites that did not receive a waiver to use the central IRB, approval was obtained from the respective governing IRBs, and documentation of approval was submitted to the sponsor prior to initiating any study procedures. All registry subjects were required to provide written informed consent prior to participation.
: Not applicable.
: ASP has nothing to disclose. DAP is an employee of CorEvitas, LLC and may own company stock; he is also a consultant for Novartis, Regeneron, and Roche. SF and KF are employees of Sanofi and may hold shares and/or stock options in the company. TSB is an employee of CorEvitas, LLC. KE was an employee of CorEvitas, LLC during the development of this study. JMK has an equity interest in CorEvitas, LLC and consults for them.